Articles

Latest California Healthline Stories

KHN’s ‘What the Health?’: Congress Shelves Covid Funding for Now

The Biden administration’s request for billions more in funding to fight covid-19 hit a snag on Capitol Hill this week, as Democrats objected to Republican demands that money allocated to states but not yet spent be reclaimed. Meanwhile, the big annual spending bill about to cross the finish line addresses other health policy changes, such as giving the FDA authority to regulate “synthetic” nicotine. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Rachel Cohrs of Stat, and Jessie Hellmann of Modern Healthcare join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Which Companies Aren’t Exiting Russia? Big Pharma

U.S. and global drug manufacturers invested in Russia’s sizable pharmaceutical industry contend international humanitarian law requires they continue manufacturing and selling their products there, even while condemning the Ukraine invasion. Not everyone agrees.

One California University Has Unified Town and Gown to Fight Covid. Why Haven’t Others?

The University of California-Davis has spent close to $50 million preventing the spread of covid on campus — and among residents and workers in the adjacent city of Davis. By most accounts, this town-gown experiment has paid off nicely.

Watch: California’s Top Health Adviser on Learning to Live With Covid

KHN Senior Correspondent Samantha Young joined California Health and Human Services Secretary Mark Ghaly for an engaging conversation about how California moves forward in an environment in which covid persists, but at more manageable levels.

Patients Divided Over Alzheimer’s Drug: Is It a ‘Risk I’m Willing to Take’ or Just a ‘Magic Pill’?

Medicare has proposed limiting coverage of Aduhelm, the costly new drug to treat Alzheimer’s disease, and several prominent groups representing patients and their families are pressing the program to make it more widely available. But among individuals facing the disease, the outlook is more nuanced.